Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1573399816666200408084614 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low Rates of Screening for Hypercortisolism Among Patients With Severe Insulin Resistance Requiring U-500 Insulin.
Endocr Pract
May 2024
Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Spontaneous Remission of Acquired Generalized Lipodystrophy Presenting in the Postpartum Period.
JCEM Case Rep
February 2024
Atlantic Medical Group, Atlantic Health System, Morristown, NJ 07960, USA.
Acquired generalized lipodystrophy (AGL) is a rare condition characterized by the diffuse loss of adipose tissue resulting in hyperglycemia, severe insulin resistance, and sequelae of metabolic disease. Here, we report the case of a 32-year-old woman who developed uncontrolled hyperglycemia and significant weight loss within 2 months postpartum. Upon endocrine evaluation, she was found to have generalized loss of adiposity, hypoleptinemia, and persistent hyperglycemia despite aggressive insulin administration.
View Article and Find Full Text PDFA simplified straightforward protocol for the use of U-500 regular insulin.
Diabetes Obes Metab
February 2023
Charles R. Drew University, Los Angeles, California, USA.
Glycemic Outcomes of Hospitalized Patients on Ambulatory Humulin-R U-500 Insulin.
Endocr Pract
December 2022
Division of Endocrinology, Diabetes, & Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:
Objective: Managing hospitalized patients on ambulatory U-500 insulin is challenging because of limited guidance on how to safely adjust insulin doses during admission. We sought to evaluate glycemic outcomes in relation to inpatient insulin doses in patients receiving U-500 prior to hospitalization.
Methods: Retrospective study of hospitalized patients on ambulatory U-500 seen consecutively from January 2015 to December 2019.
Introduction: Humulin R U-500 (U-500R) utilization has increased in the past few years, raising concerns as U-500R is indicated only for patients requiring > 200 units of insulin. Thus, evidence of dispensed total daily dose (dTDD) > 200 units of prior U-100 insulin based on pharmacy claims is increasingly used as a criterion to determine appropriate switching to U-500R by payers. The study compared the treatment patterns and outcomes before and after U-500R initiation among patients who were identified with ≤ 200 units/day U-100 insulin fill in order to understand the appropriateness of switching.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!